CStone Submits Sugemalimab for Stage III Lung Cancer EMA Approval
March 24, 2025
CStone Pharmaceuticals, a biopharmaceutical company dedicated to developing innovative cancer therapies, announced the submission of a Type II variation application to the European Medicines Agency (EMA) for sugemalimab.